Skip to content
2000
Volume 19, Issue 8
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Cervical cancer is the second most common malignancy among women worldwide. While more than 90% of cervical cancers carry one or more high risk HPV types, the exact relationship between HPV oncoproteins and signaling pathways alterations in cervical cancer remains to be clarified. Vaccines and targeted therapies are today considered of great potential for the improvement of patients' outcome. This review will focus on the interaction of HPV with cervical cancer pathway activations. Next generation high throughput screening technologies for molecular and protein profiling as well as innovative logistics, necessary for the implementation of the personalized care of cervical cancer patients will be discussed.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/138161213804805577
2013-03-01
2025-05-31
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/138161213804805577
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test